Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Meiji Seika Pharma General Information
Meiji Seika Pharma is a leading Japanese pharmaceutical company with a strong focus on infectious diseases—especially antibacterial drugs—holding over 50% market share in injectable penicillin-based antibacterials in Japan. The company also markets treatments for CNS disorders and allergies and is active in the development of generic anticancer drugs and biosimilars. It has an established presence in both branded and generic pharmaceuticals as well as contract manufacturing services.
Contact Information
Primary Industry
Biotech
Corporate Office
Tokyo, Tokyo-to
Japan
Japan
Drug Pipeline
No pipeline data available
Key Partnerships
Academic collaborations with Kyoto University, Kumamoto University, Juntendo University, Kitasato University, partnerships for biosimilar/generic drug development
Meiji Seika Pharma Funding
No funding data available
To view Meiji Seika Pharma's complete valuation and funding history, request access »